Gabapentin inhibits central sensitization during migraine

Neural Regeneration Research

Volumn 8, Issue 32, 2013, Pages 3003-3012

  Zhang, Yanbo ^a,b   Shao, Guo ^c   Zhang, Wei ^c   Li, Sijie ^a   Niu, Jingzhong ^b   Hu, Dongmei ^b   Yang, Mingfeng ^b   Ji, Xunming ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

^c BAOTOU MEDICAL COLLEGE   (China)

Author keywords

Calcitonin gene related peptide; Excitatory amino acid; Gamma aminobutyric acid; Glutamic acid; Grants supported paper; Ionic excitatory amino acid receptors; Migraine; Neural regeneration; Neurons; Neuroregeneration; Nitric oxide synthase; Nuclei of trigeminal nerve; Protein kinase c

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 4 AMINOBUTYRIC ACID; ASPARTIC ACID; BETA ACTIN; FLUNARIZINE; GABAPENTIN; GLUTAMIC ACID; PROTEIN KINASE C; SERINE; AMINO ACID; PROTEIN KINASE C INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM SENSITIZATION; CEREBROSPINAL FLUID; CONTROLLED STUDY; ELECTROPHYSIOLOGY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MIGRAINE; NERVE CELL MEMBRANE POTENTIAL; NERVE CELL STIMULATION; NONHUMAN; PROTEIN EXPRESSION; RAT; TRIGEMINAL NUCLEUS; WESTERN BLOTTING; BEHAVIOR CHANGE; DRUG EFFICACY; ELECTROSTIMULATION; NERVE EXCITABILITY; QUANTITATIVE ANALYSIS; TRIGEMINUS GANGLION;

EID: 84889864738     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.32.003     Document Type: Article

References (26)

1. Gordon J, Lister S, Prettyjohns M, et al. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J Med Econ. 2012;15(2):207-218.
2. Stidd DA, Wuollet AL, Bowden K, et al. Peripheral nerve stimulation for trigeminal neuropathic pain. Pain Physician. 2012;15(1):27-33.
3. Tepper SJ, Kori SH, Borland SW, et al. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache. 2012;52(1):37-47.
4. Kanner AM. Are antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality? Curr Pain Headache Rep. 2011;15(3):164-169.
5. Baillie JK, Power I. The mechanism of action of gabapentin in neuropathic pain. Curr Opin Investig Drugs. 2006; 7(1):33-39.
6. Maneuf YP, Luo ZD, Lee K. alpha2delta and the mechanism of action of gabapentin in the treatment of pain. Semin Cell Dev Biol. 2006;17(5):565-570.
7. Hershey AD, Winner P, Kabbouche MA, et al. Headaches. Curr Opin Pediatr. 2007;19(6):663-669.
8. Gilmore B, Michael M. Treatment of acute migraine headache. Am Fam Physician. 2011;83(3):271-280.
9. Evans RW, Johnston JC. Migraine and medical malpractice. Headache. 2011;51(3):434-440.
10. Biondi DM. Is migraine a neuropathic pain syndrome? Curr Pain Headache Rep. 2006;10(3):167-178.
11. Charles A. Advances in the basic and clinical science of migraine. Ann Neurol. 2009;65(5):491-498.
12. Buzzi MG, Moskowitz MA. The pathophysiology of migraine: year 2005. J Headache Pain. 2005;6(3):105-111.
13. Burstein R, Jakubowski M, Garcia-Nicas E, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol. 2010;68(1):81-91.
14. Young WB. Allodynia as a complication of migraine: background and management. Curr Treat Options Neurol. 2009;11(1):3-9.
15. Schürks M, Diener HC. Migraine, allodynia, and implications for treatment. Eur J Neurol. 2008;15(12):1279-1285.
16. Oshinsky ML. Insights from experimental studies into allodynia and its treatment. Curr Pain Headache Rep. 2006;10(3):225-230.
17. Lipton RB, Bigal ME, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63(2):148-158.
18. Sarchielli P, Di Filippo M, Nardi K, et al. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep. 2007;11(5):343-351.
19. Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris). 2005;161(6-7):658-660.
20. Durham PL, Garrett FG. Neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine. Cephalalgia. 2009; 29(Suppl 2):1-6.
21. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9(3):285-298.
22. Cheng JK, Ji RR. Intracellular signaling in primary sensory neurons and persistent pain. Neurochem Res. 2008; 33(10):1970-1978.
23. Ji RR, Kawasaki Y, Zhuang ZY, et al. Protein kinases as potential targets for the treatment of pathological pain. Handb Exp Pharmacol. 2007;177:359-389.
24. Teicher BA. Protein kinase C as a therapeutic target. Clin Cancer Res. 2006;12(18):5336-5345.
25. Wang RF, Yu SY, Liu RZ, et al. NF-κB in midbrain periaqueductal gray induced by electrical stimulation of dura near superior sagittal sinus in rats. Zhonghua Shenjingke Zazhi. 2007;40(11):771-774.
26. Xu W, Shi ZC, Wei JC, et al. Changes on degranulation of mast cells and neurogenic inflammation-related factors in the dura mater of the rat model of migraine. Zhonghua Shenjingke Zazhi. 2011;44(8):563-567.